AstraZeneca has received more than $1 billion from the U.S. Health Department’s Biomedical Advanced Research and Development Authority to develop a coronavirus vaccine from the University of Oxford
The United States has secured almost a third of the first one billion doses planned for AstraZeneca's experimental Covid-19 vaccine
Alex Azar, U.S. Health Secretary said, “This contract with AstraZeneca is a major milestone in Operation Warp Speed's work toward a safe, effective, widely available vaccine by 2021,”
The vaccine, previously known as ChAdOx1 nCoV-19 and now as AZD1222, was developed by the University of Oxford and licensed to AstraZeneca. The first doses of AZD1222 are expected to be delivered in October.
